Search Medical Condition
Please enter condition
Please choose location

Nasopharyngeal Cancer Clinical Trials

A listing of Nasopharyngeal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (104) clinical trials

Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma

Primary: - To evaluate the efficacy of capecitabine in combination with oxaliplatin (XELOX) in terms of overall response rate (based on RECIST criteria) in patients with metastatic NPC without prior chemotherapy for relapse. Secondary: - To evaluate the efficacy profile of oxaliplatin (XELOX) in patients with metastatic NPC in terms ...


Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients

Nasopharyngeal carcinomas (NPCs) are highly radiosensitive tumors, and the primary treatment of NPCs is radiotherapy.1 Because most patients who have NPC are at advanced stages when initially seen, local failures in terms of persistence or recurrence are not infrequent after primary radiotherapy.2,3 Local regional relapse without the presence of distant ...

Phase N/A

Molecular Mechanism of Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC), a human malignancy derived from the nasopharyngeal epithelial cells, is occurring highly frequently in Taiwan. Of note, the average ages of NPC individuals are usually ten years younger than those of patients with other head and neck cancers. Clinically, this early onset and high incidence of metastasis ...

Phase N/A

Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma

The proposed study will test the safety and efficacy of sodium valproate in the induction of Epstein-Barr virus (EBV) lytic cycle antigen expression in tumor tissue of patients undergoing primary therapy for nasopharyngeal carcinoma. Up to 20 patients will be given valproic acid for 2 weeks. The primary surrogate endpoint ...


Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients

In order to improve locoregional control and to eradicate micrometastases for patients with locally advanced nasopharyngeal carcinoma (NPC), induction chemotherapy followed by concurrent chemoradiotherapy has been the preferred therapeutic approach.Although it would be of great advantage to identify non-responder during or immediately after therapy to formulate an alternative treatment strategy, ...

Phase N/A

Markers for Cancer in Families at High Risk of Nasopharyngeal Cancer

OBJECTIVES: - Evaluate the clinical utility of serum Epstein-Barr virus antibody testing for the identification of individuals at increased risk of nasopharyngeal carcinoma (NPC) within high-risk NPC multiplex families. OUTLINE: Participants undergo ear, nose, and throat examination (i.e., collection of blood, saliva, nasopharyngeal tissue, and urine and undergo a nasopharyngeal ...

Phase N/A

Trial of E10A in Head and Neck Cancer

Angiogenesis, the formation of new blood vessel from existing vessels, is essential for tumor growth and metastasis. Antiangiogenic therapies inhibit the growth of genetically stable endothelial cells, and most tumors should starve to death with little acquired resistance. Endostatin has been shown to block endothelial cell proliferation, survival, and migration. ...


Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

OBJECTIVES: Primary - To determine progression-free survival (PFS 1) of patients with metastatic or locally recurrent Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma treated with gemcitabine hydrochloride and carboplatin followed EBV-specific cytotoxic T-lymphocytes (CTL). Secondary - To determine progression-free survival (PFS 2) of these patients during the immunotherapy portion of this study. ...


A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Locoregionally advanced nasopharyngeal carcinoma (NPC)(stage III, IV in UICC 2002 Classification) can be divided into two groups according to the risk of metastasis: high-risk metastasis group (T4 or N2-3) and low-risk metastasis group (T3N0-1). In low-risk metastasis group, concurrent chemoradiotherapy (CCRT) might decrease local recurrence and distance metastasis, which benefits ...


Phase Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage AB Nasopharyngeal Carcinoma

Concurrent chemoradiation is the standard treatment for locally advanced NPC. The survival benefit gained from adding neoadjuvant chemotherapy to concurrent chemoradiation has never been defined. In the present trail, we hope to assess the tolerance and survival benefits of neoadjuvant chemotherapy followed by concurrent chemoradiation in patients with stage ⅣAB ...